UK Markets closed

AstraZeneca PLC (AZN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
52.61+0.01 (+0.02%)
At close: 1:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close52.60
Open51.58
Bid52.62 x 3100
Ask52.70 x 1800
Day's range51.44 - 52.77
52-week range36.15 - 64.94
Volume14,783,164
Avg. volume5,039,663
Market cap136.159B
Beta (5Y monthly)0.30
PE ratio (TTM)55.38
EPS (TTM)0.95
Earnings dateN/A
Forward dividend & yield1.40 (2.66%)
Ex-dividend date13 Aug 2020
1y target est60.63
  • 3 Key Advantages Moderna Holds Over Pfizer and AstraZeneca
    Motley Fool

    3 Key Advantages Moderna Holds Over Pfizer and AstraZeneca

    They could add up to make Moderna a much bigger winner for investors than either of the two big pharma stocks.

  • Why AstraZeneca's Potential Vaccine Is More Exciting Than You Think
    Motley Fool

    Why AstraZeneca's Potential Vaccine Is More Exciting Than You Think

    In the last three weeks, the world has let out a collective sigh of relief on positive news from coronavirus vaccine trials reported by Pfizer (NYSE: PFE) and partner BioNTech (NASDAQ: BNTX), Moderna (NASDAQ: MRNA), and AstraZeneca (NASDAQ: AZN). Despite the market's reaction, I think investors have more to be excited about from the potential AstraZeneca vaccine than its efficacy data suggests. AstraZeneca and the University of Oxford's recent announcement that their vaccine candidate had 70% overall effectiveness at preventing COVID-19 requires a little more digging.

  • UK inks deal for 2 million more doses of Moderna COVID-19 vaccine
    Yahoo Finance UK

    UK inks deal for 2 million more doses of Moderna COVID-19 vaccine

    This is on top of the 5 million doses it already put its name down for two weeks ago, and is subject to approval from the Medicines and Healthcare products Regulatory Agency (MHRA).